The Straits Times
https://str.sg/JrDp
They can read the article in full after signing up for a free account.
Share link:
Or share via:
Sign up or log in to read this article in full
Sign up
All done! This article is now fully available for you
Read now
Get unlimited access to all stories at $0.99/month for the first 3 months.
Get unlimited access to all stories at $0.99/month for the first 3 months.
including the ST News Tablet worth $398.
Let s go!
Spin the wheel for ST Read and Win now.
Let s go!
The first edition of international art fair Art SG has been postponed yet again, this time to January next year. The Singapore-based fair will now run from Jan 20 to 23 at the Marina Bay Sands Expo and Convention Centre.
Pacific Prime acquires CXA Group s brokerages 10th February 2021
ANTARA/Business Wire
Singapore (Antara/Business Wire)- Global insurance brokerage Pacific Prime has solidified its foothold in Asia Pacific by acquiring the Hong Kong and Singapore brokerage arms of CXA Group, an insurtech company that has exited this sector to focus on its cloud-based enterprise SaaS business. The acquisition deal took place on February 4th, 2021.
CXA s insurtech business is backed by HSBC, Singtel Innov8, the Singapore Economic Development Board s investment arm EDBI and B Capital Group, the venture firm of Facebook co-founder Eduardo Saverin.
The acquisition of CXA Group’s brokerage arms in Hong Kong and Singapore is a breakthrough, as Pacific Prime seeks to continually expand in the Asia Pacific region and globally. The acquisition gives Pacific Prime the technology to offer full-flex and simplified flex solutions to all of its clients around the world.
Moderna Inc won approval from Singapore for its Covid vaccine and signed a deal to sell doses to the Philippines, becoming the fourth supplier to get regulatory clearance in Southeast Asia.
(Bloomberg) Moderna Inc. won approval from Singapore for its Covid vaccine and signed a deal to sell doses to the Philippines, becoming the fourth supplier to get regulatory clearance in Southeast Asia.
Shots by AstraZeneca Plc, Pfizer Inc.-BioNTech SE and Sinovac Biotech Ltd.